ArticleBreast cancer research and treatment2025

Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi.

Jeffrey Franks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.